Shares of agilon health (AGL) more than doubled on Thursday, surging 118% to $60.66 after the company reported a first-quarter profit that significantly exceeded Wall Street expectations. The stock hit an intraday high of $63.75 before settling, marking a dramatic turnaround for the Medicare-focused physician platform that had been under pressure in recent quarters.
The company posted first-quarter net income of $49 million, a sharp increase from $12 million in the same period last year, despite a 7% decline in revenue to $1.42 billion. Adjusted EBITDA also improved substantially, climbing to $54 million from $21 million a year ago. The results were driven by disciplined cost management and early returns from investments in data analytics and clinical initiatives.
In a strategic move, agilon named Tim O'Rourke as its new CEO, effective May 7, succeeding Ronald A. Williams, who will remain as executive chairman. O'Rourke steps into the role at a critical juncture, with the company facing pressure to demonstrate that a shrinking membership base does not necessarily mean weaker financial performance. The company's platform now serves 536,000 members, down 11% from the prior year, including 426,000 enrolled in Medicare Advantage and 110,000 under the ACO REACH model.
The earnings beat and leadership change prompted multiple analysts to upgrade the stock. Jefferies analyst Jack Slevin raised his rating from Hold to Buy and increased his price target from $27.50 to $48, citing clearer trends and supportive Medicare Advantage rates for 2026 and 2027. Deutsche Bank's George Hill also upgraded agilon to Buy, lifting his target to $49 from $33, pointing to the boosted EBITDA outlook and a more favorable operating environment.
Agilon raised its full-year 2026 guidance, now forecasting revenue between $5.68 billion and $5.81 billion, and adjusted EBITDA in the range of $10 million to $40 million—a significant improvement from the prior outlook that spanned a $15 million loss to a $15 million gain. The guidance upgrade reflects the company's confidence in its value-based care model, which partners with physician groups to manage costs and improve patient outcomes.
However, the company remains heavily reliant on a narrow customer base. According to its 10-Q filing, Medicare Advantage payers accounted for substantially all of agilon's first-quarter revenue, with a handful of large payers dominating the total. While stronger contracts could boost margins, the concentration also exposes the company to risks from payer disputes, rate changes, or spikes in medical costs.
Legal challenges continue to loom. In its latest quarterly filing, agilon disclosed that a consolidated securities class-action lawsuit is progressing through discovery. The plaintiffs allege misstatements between April 2021 and February 2024 related to financial guidance, medical margins, adjusted EBITDA, growth plans, and data management. Some claims were dismissed in 2025, but others remain active.
Despite these headwinds, investors appear optimistic about the company's direction under new leadership. O'Rourke has emphasized execution over marketing, pointing to agilon's upgraded platform in data, analytics, contracting, and cost management as key enablers for future growth. The stock's dramatic rally suggests the market is giving him room to prove that the turnaround is real.
